<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39839644</PMID><DateRevised><Year>2025</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Efficacy of an intervention to increase therapeutic adherence in patients with secondary prevention for cardiovascular disease: a study protocol for a randomized controlled trial.</ArticleTitle><Pagination><StartPage>1510744</StartPage><MedlinePgn>1510744</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1510744</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2024.1510744</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Cardiovascular diseases represent the leading cause of mortality worldwide. This category includes cerebrovascular disease, ischemic heart disease, and peripheral vascular disease. Secondary prevention is effective for patients with a history of cardiovascular events, with antihypertensives, statins, and acetylsalicylic acid being the most prescribed drugs. Therapeutic adherence is crucial, as the lack of it increases morbidity, mortality, reduces quality of life, and raises healthcare costs. However, less than half of patients adhere to all three drugs within the first year post-event. Furthermore, non-adherence is more pronounced in primary care.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">Based on our hypothesis that in patients undergoing cardiovascular secondary prevention, an intervention grounded in the application of the Chronic Care Model improves adherence to the three preventive drugs, this study aims to evaluate the efficacy of a health education intervention, which implements this model, to increase adherence in patients with cardiovascular disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">An open-label randomized controlled trial will be conducted, selecting patients who meet inclusion criteria through consecutive non-probability sampling. Random assignment will be performed using the random number table method. Based on a therapeutic adherence rate of 50% in the control group and 80% in the intervention group, with a type I error of 5% (95% confidence interval), a type II error of 20% (80% power), and accounting for a 15% loss to follow-up, the final sample size will be of 45 patients per group. Follow-up will last for 1&#x202f;year. Following data collection, univariate, bivariate, and multivariate analyses will be performed to isolate confounding factors and assess the intervention's impact on adherence.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">If the results obtained in this study are favorable and the intervention is successful in enhancing therapeutic adherence, its applicability would be substantial, representing a feasible intervention for implementation in primary care. This approach addresses a significant public health issue, namely the lack of therapeutic adherence and its associated consequences. Moreover, this is particularly pertinent for high-risk patients, such as those in secondary prevention, given that cardiovascular disease remains the leading cause of mortality in developed countries. This trial has been registered at clinicalTrials.gov, https://clinicaltrials.gov/study/NCT06510946.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Lid&#xf3;n-Mu&#xf1;oz, Quesada, Gil-Guill&#xe9;n and Orozco-Beltr&#xe1;n.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Lid&#xf3;n-Mu&#xf1;oz</LastName><ForeName>Francisco Manuel</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Dr. Balmis General University Hospital of Alicante, Babel Health Centre, Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Quesada</LastName><ForeName>Jos&#xe9; Antonio</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine, Miguel Hern&#xe1;ndez University of Elche, San Juan de Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Network on Chronicity Primary Care and Prevention and Health Promotion, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Primary Care Research Center, Miguel Hernandez University of Elche, San Juan de Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil-Guill&#xe9;n</LastName><ForeName>Vicente Francisco</ForeName><Initials>VF</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine, Miguel Hern&#xe1;ndez University of Elche, San Juan de Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Network on Chronicity Primary Care and Prevention and Health Promotion, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Primary Care Research Center, Miguel Hernandez University of Elche, San Juan de Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orozco-Beltr&#xe1;n</LastName><ForeName>Domingo</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine, Miguel Hern&#xe1;ndez University of Elche, San Juan de Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Network on Chronicity Primary Care and Prevention and Health Promotion, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Primary Care Research Center, Miguel Hernandez University of Elche, San Juan de Alicante, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT06510946</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiovascular diseases</Keyword><Keyword MajorTopicYN="N">chronic disease</Keyword><Keyword MajorTopicYN="N">coronary disease</Keyword><Keyword MajorTopicYN="N">primary health care</Keyword><Keyword MajorTopicYN="N">secondary prevention</Keyword><Keyword MajorTopicYN="N">treatment adherence and compliance</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>22</Day><Hour>4</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39839644</ArticleId><ArticleId IdType="pmc">PMC11747688</ArticleId><ArticleId IdType="doi">10.3389/fmed.2024.1510744</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Organizaci&#xf3;n Mundial de la Salud  (2003). Organizaci&#xf3;n Panamericana de la Salud 2004. Adherencia a los tratamientos a largo plazo: pruebas para la acci&#xf3;n. Available at:https://www3.paho.org/hq/dmdocuments/2012/WHO-Adherence-Long-Term-Therapies-Spa-2003.pdf [Accessed August 20, 2024].</Citation></Reference><Reference><Citation>Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. . Medication compliance and persistence: terminology and definitions. Value Health. (2008) 11:44&#x2013;7. doi: 10.1111/j.1524-4733.2007.00213.x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1524-4733.2007.00213.x</ArticleId><ArticleId IdType="pubmed">18237359</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Adherence to long term therapies: Evidence for action. Geneva: Ginebra; (2004). 2003 p.</Citation></Reference><Reference><Citation>Soriano JB, Rojas-Rueda D, Alonso J, Ant&#xf3; JM, Cardona PJ, Fern&#xe1;ndez E, et al. . The burden of disease in Spain: results from the global burden of disease 2016. Med Clin (Barc). (2018) 151:171&#x2013;90. doi: 10.1016/j.medcli.2018.05.011, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medcli.2018.05.011</ArticleId><ArticleId IdType="pubmed">30037695</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindstrom M, DeCleene N, Dorsey H, Fuster V, Johnson CO, LeGrand KE, et al. . Global burden of cardiovascular diseases and risks collaboration, 1990&#x2013;2021. J Am Coll Cardiol. (2022) 80:2372&#x2013;425. doi: 10.1016/j.jacc.2022.11.001, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.11.001</ArticleId><ArticleId IdType="pubmed">36517116</ArticleId></ArticleIdList></Reference><Reference><Citation>Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. (2012) 125:882&#x2013;7.e1. doi: 10.1016/j.amjmed.2011.12.013, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2011.12.013</ArticleId><ArticleId IdType="pubmed">22748400</ArticleId></ArticleIdList></Reference><Reference><Citation>Red&#xf3;n J, Us&#xf3; R, Trillo JL, L&#xf3;pez C, Morales-Olivas F, Navarro J, et al. . Number of drugs used in secondary cardiovascular prevention and late survival in the population of Valencia community. Spain Int J Cardiol. (2019) 293:260&#x2013;5. doi: 10.1016/j.ijcard.2019.05.071, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2019.05.071</ArticleId><ArticleId IdType="pubmed">31229263</ArticleId></ArticleIdList></Reference><Reference><Citation>Perseguer Z. Adherencia terap&#xe9;utica en hipertensi&#xf3;n arterial en la farmacia comunitaria [master's thesis]. San Juan de Alicante: Universidad Miguel Hern&#xe1;ndez de Elche; (2012).</Citation></Reference><Reference><Citation>Ryan R, Santesso N, Lowe D, Hill S, Grimshaw J, Prictor M, et al. . Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews. Cochrane Database Syst Rev. (2014) 2022:CD007768. doi: 10.1002/14651858.CD007768.pub3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD007768.pub3</ArticleId><ArticleId IdType="pmc">PMC6491214</ArticleId><ArticleId IdType="pubmed">24777444</ArticleId></ArticleIdList></Reference><Reference><Citation>De Frutos E, Lorenz G, Manzotti C, Esp&#xed;nola A, Hern&#xe1;ndez AR, Val Jim&#xe9;nez A, et al. . Cumplimiento terap&#xe9;utico en pacientes con enfermedad cardiovascular. Clin Invest Arterioscl. (2008) 20:8&#x2013;13. doi: 10.1016/S0214-9168(08)72574-9, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0214-9168(08)72574-9</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. . Polypill strategy in secondary cardiovascular prevention. N Engl J Med. (2022) 387:967&#x2013;77. doi: 10.1056/NEJMoa2208275, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2208275</ArticleId><ArticleId IdType="pubmed">36018037</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med. (1997) 102:43&#x2013;9. doi: 10.1016/S0002-9343(97)00467-1, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9343(97)00467-1</ArticleId><ArticleId IdType="pubmed">9217586</ArticleId></ArticleIdList></Reference><Reference><Citation>Conthe P, M&#xe1;rquez Contreras E. Una aproximaci&#xf3;n multidisciplinar al problema de la adherencia terap&#xe9;utica en las enfermedades cr&#xf3;nicas: estado de la situaci&#xf3;n y perspectivas de futuro [Internet]. Spain; (2012). Available at:www.enfermeriacantabria.com/web_enfermeriacantabria/docs/documento_consenso_2.pdf [Accessed September 15, 2024].</Citation></Reference><Reference><Citation>Wagner EH, Austin BT, Von Korff M. Organizing Care for Patients with chronic illness. Milbank Q. (1996) 74:511&#x2013;44. doi: 10.2307/3350391, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/3350391</ArticleId><ArticleId IdType="pubmed">8941260</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. (2005) 353:487&#x2013;97. doi: 10.1056/NEJMra050100, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra050100</ArticleId><ArticleId IdType="pubmed">16079372</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathes T, Jaschinski T, Pieper D. Adherence influencing factors a systematic review of systematic reviews. Arch Public Health. (2014) 72:1&#x2013;9. doi: 10.1186/2049-3258-72-37, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2049-3258-72-37</ArticleId><ArticleId IdType="pmc">PMC4323150</ArticleId><ArticleId IdType="pubmed">25671110</ArticleId></ArticleIdList></Reference><Reference><Citation>Krousel-Wood M, Holt E, Joyce C, Ruiz R, Dornelles A, Webber L, et al. . Differences in cardiovascular disease risk when antihypertensive medication adherence is assessed by pharmacy fill versus self-report: the cohort study of medication adherence among older adults (CoSMO). J Hypertens. (2015) 33:412&#x2013;20. doi: 10.1097/HJH.0000000000000382, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0000000000000382</ArticleId><ArticleId IdType="pmc">PMC4514519</ArticleId><ArticleId IdType="pubmed">25304468</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>